stockrow
Saturday 7 November 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
- Revenue
- +15.9%
- EPS
- +0.91%
- Free cash flow
- −189.0%
Quarter to June 2026, against a year earlier
0.51
0.01
+2.00%
Follow VBIO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
7.91 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(1.91) | — | — | — | |
P/B ratio |
0.68 | — | — | — | |
Price to Tangible BV |
1.14 | — | — | — | |
EV/Sales |
1.26 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(0.10) | — | — | — | |
EV/FCF |
(0.10) | — | — | — | |
Quick Ratio |
5.44 | 19.57 | 2.76 | 0.69 | |
Current Ratio |
5.86 | 20.13 | 3.31 | 1.11 | |
Net Debt/EBITDA |
1.39 | 2.93 | 0.06 | (0.99) | |
Debt/Assets |
0.00% | 20.42% | 18.05% | 22.75% | |
Debt/Equity |
0.00 | 0.27 | 0.37 | 0.62 | |
Asset Turnover |
0.10 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.76 | 0.78 | 0.72 | |
Capex/Depreciation |
0.00 | (0.25) | (0.01) | (0.05) | |
Interest Coverage |
620.75 | (15.73) | (8.69) | (9.30) | |
Research and Development Expense of Revenue |
587.67% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,013.70% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.36 | 0.18 | 0.15 | 0.18 | |
Share Based Compensation of Revenue |
95.21% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.81 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(341.51%) | — | — | — | |
Free Cash Flow Yield |
(159.64%) | — | — | — | |
Revenue per Share |
2.77 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(37.80) | (30.89) | (43.46) | (39.06) | |
Capex per Share |
(0.19) | (0.34) | (0.06) | (0.42) | |
Free Cash Flow per Share |
(37.99) | (31.23) | (43.52) | (39.48) | |
Cash per Share |
65.34 | 170.82 | 62.58 | 15.59 | |
Shareholders Equity per Share |
105.89 | 326.46 | 160.87 | 87.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
105.89 | 326.46 | 160.87 | 87.91 | |
Free Cash Flow |
(2.01) | (2.31) | (5.02) | (5.34) | |
Working Capital |
3.10 | 12.36 | 6.04 | 0.34 | |
Capital Expenditures |
(0.01) | (0.02) | (0.01) | (0.06) | |
Net Current Asset Value |
3.10 | 5.57 | (11.01) | (17.21) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.07 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Receivables |
0.01 | — | — | — | |
Average Payables |
0.40 | 0.19 | 0.53 | 0.44 | |
Average Inventory |
0.37 | — | 0.53 | 0.53 | |
Average Assets |
4.81 | 17.21 | 21.00 | 18.49 | |
Average Common Equity |
4.21 | 9.67 | 7.05 | 3.97 |
Columns are period end dates · fundamentals updated 26 Oct 2026